Suchen
Kodiak Sciences Inc
KODZur Watchlist hinzufügen
41.010USD
-2.670-6.11%
Handelsschluss 05/08, 16:00（ET）Kurse um 15 Minuten verzögert
2.57BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Kodiak Sciences Inc Unternehmen
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences Inc Informationen
BörsenkürzelKOD
Name des UnternehmensKodiak Sciences Inc
IPO-datumOct 04, 2018
CEOPerlroth (Victor)
Anzahl der mitarbeiter109
WertpapierartOrdinary Share
GeschäftsjahresendeOct 04
Addresse1250 Page Mill Rd
StadtPALO ALTO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94304
Telefon16502810850
Websitehttps://kodiak.com/
BörsenkürzelKOD
IPO-datumOct 04, 2018
CEOPerlroth (Victor)
Führungskräfte von Kodiak Sciences Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
211.93K
+13.50%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
211.93K
+13.50%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
31.83%
Perlroth (Victor D)
4.79%
BlackRock Institutional Trust Company, N.A.
4.71%
Braidwell LP
3.31%
State Street Investment Management (US)
2.77%
Andere
52.60%
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
31.83%
Perlroth (Victor D)
4.79%
BlackRock Institutional Trust Company, N.A.
4.71%
Braidwell LP
3.31%
State Street Investment Management (US)
2.77%
Andere
52.60%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
45.55%
Investment Advisor
22.85%
Investment Advisor/Hedge Fund
15.33%
Individual Investor
5.18%
Research Firm
3.11%
Private Equity
1.36%
Endowment Fund
1.11%
Pension Fund
0.23%
Bank and Trust
0.18%
Andere
5.10%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
311
60.04M
96.04%
+7.96M
2025Q4
265
48.79M
79.98%
+1.64M
2025Q3
248
41.93M
79.39%
-9.11M
2025Q2
273
46.04M
87.25%
-8.67M
2025Q1
302
46.32M
87.78%
-8.84M
2024Q4
308
44.88M
85.29%
-7.98M
2024Q3
318
42.74M
81.24%
-12.36M
2024Q2
326
43.49M
82.78%
-12.58M
2024Q1
345
46.64M
88.83%
-7.18M
2023Q4
377
44.39M
84.60%
-13.12M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Baker Bros. Advisors LP
19.92M
32.66%
+2.61M
+15.07%
Dec 31, 2025
Perlroth (Victor D)
3.00M
4.91%
+300.00K
+11.13%
Mar 25, 2026
BlackRock Institutional Trust Company, N.A.
2.95M
4.83%
+546.31K
+22.77%
Dec 31, 2025
Braidwell LP
2.07M
3.4%
+2.07M
--
Dec 31, 2025
State Street Investment Management (US)
1.73M
2.84%
+899.57K
+108.06%
Dec 31, 2025
RTW Investments L.P.
1.49M
2.44%
+1.49M
--
Dec 31, 2025
TCG Crossover Management, LLC
1.45M
2.37%
+300.00K
+26.19%
Dec 31, 2025
ICONIQ Capital, LLC
1.27M
2.08%
--
--
Dec 31, 2025
T. Rowe Price Associates, Inc.
1.14M
1.86%
+673.93K
+145.42%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Fidelity Enhanced Small Cap ETF
0.18%
iShares Micro-Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.11%
Invesco RAFI US 1500 Small-Mid ETF
0.06%
iShares Health Innovation Active ETF
0.06%
iShares Russell 2000 Value ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.05%
ProShares Hedge Replication ETF
0.03%
ProShares UltraPro Russell2000
0.03%
Proshares Ultra Russell 2000
0.02%
Mehr Anzeigen
Fidelity Enhanced Small Cap ETF
Anteil0.18%
iShares Micro-Cap ETF
Anteil0.11%
Vanguard US Momentum Factor ETF
Anteil0.11%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.06%
iShares Health Innovation Active ETF
Anteil0.06%
iShares Russell 2000 Value ETF
Anteil0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0.05%
ProShares Hedge Replication ETF
Anteil0.03%
ProShares UltraPro Russell2000
Anteil0.03%
Proshares Ultra Russell 2000
Anteil0.02%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
